Homology Medicines

Arthur Tzianabos, Ph.D., President and CEO

Oct. 12 | 5:15pm | AVROBIO Ballroom

Bedford, MA

(NASDAQ: FIXX)

In-person Presentation

Homology Medicines is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors to precisely and efficiently deliver genetic medicines in vivo, either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing, and commercializing therapeutics with a particular focus on rare diseases. The company’s intellectual property covers its family of 15 AAVHSCs. Homology believes that its compelling data, scientific expertise, product development strategy, manufacturing capabilities, and intellectual property position it as a leader in the development of genetic medicines.

www.homologymedicines.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions